Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Crinetics Pharmaceuticals ( (CRNX) ) has shared an announcement.
Crinetics Pharmaceuticals has appointed Isabel Kalofonos as the Chief Commercial Officer to lead the commercial strategy for launching paltusotine, an innovative treatment for acromegaly. With over 20 years of experience in the pharmaceutical and biotech industry, Kalofonos’s appointment suggests a strategic move by Crinetics to strengthen its market position and enhance its pipeline commercialization efforts, potentially impacting stakeholders by advancing new treatments in the endocrine disorders sector.
More about Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company specializing in the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Its key development candidate, paltusotine, is an investigational oral therapy for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. The company also develops other orally delivered, small molecule drugs for various endocrine conditions.
YTD Price Performance: 50.82%
Average Trading Volume: 730,442
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.98B
Find detailed analytics on CRNX stock on TipRanks’ Stock Analysis page.
